Ligand Pharmaceuticals reported 68.1 in PE Price to Earnings for its fiscal quarter ending in September of 2026.





Pe Change Date
Amgen 18.6 0.53 Sep/2026
Anika Therapeutics 47.54 27.2 Jun/2024
Arrowhead Research 39.19 0 Jun/2026
Baxter International 20.35 131.6 Sep/2026
Bristol-Myers Squibb 10.44 5.7 Sep/2026
Eli Lilly 64.5 31.61 Sep/2026
Enviri Corporation 121.21 92.59 Jun/2023
Gilead Sciences 17.68 4.18 Sep/2026
GlaxoSmithKline 9.72 0.9 Sep/2026
Glaxosmithkline 15.17 0.08 Sep/2026
Intrexon 7.54 221.44 Dec/2021
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Ligand Pharmaceuticals 68.1 16.21 Sep/2026
Merck 34.36 2.11 Sep/2026
Pacira 80.9 45.22 Sep/2026
Pfizer 15.2 3.72 Sep/2026
Rigel Pharmaceuticals 8.61 8.4 Mar/2025
Veracyte 29.55 13.22 Sep/2026